Prof. Dr. Matthias Dobbelstein
Matthias Dobbelstein is a Principal Investigator in SP5 and a member of the Curriculum Committee.
His research focuses on the tumor suppressor p53, its regulator MDM2, and the cellular response to DNA damage - key processes in cancer development. By targeting signaling cascades and nucleic acid synthesis, his work aims to improve cancer therapies and explore novel strategies against virus-infected cells.
Prof. Dobbelstein established the PhD Program of Molecular Medicine in 2010 and held its chair from 2010-2015. He has been the spokesperson for the EKFS-funded Promotionskolleg Genome Dynamic and Epigenomics and of the DFG College for Clinician Scientists Cell Dynamics in Disease and Therapy since 2017 and an associated member of the Max Planck Institute of Biophysical Chemistry since 2020.
| Year | Position |
|---|---|
| Since 2005 | Director, Institute of Molecular Oncology, UMG |
| 2004-2005 | Professor of Molecular Oncology, Medical Biotechnology Center, University of Southern Denmark, Odense, Denmark |
| 1999 | Postdoctoral Award for Virus Research, Robert Koch Foundation |
| 1998 | Research Award, Hessian Cancer Society |
| 1997-2004 | Group Leader, Institute of Virology, Philipps University Marburg |
| 1994 | Dr. med. (“summa cum laude”), University of Munich, LMU (Supervisor: Prof. Dr. Ellen Fanning) |
| 1993-1996 | Postdoctoral Fellow with Prof. Dr. T. Shenk, Virology, Department of Molecular Biology, Princeton University, NJ (USA) |
| 1993-1996 | Scholarship Infectious Biology (AIDS scholarship), German Cancer Research Center Heidelberg |
| 1986-1992 | Scholarship for Highly Gifted Students from the State of Bavaria |
| 1986-1992 | Scholarship from the German Academic Scholarship Foundation |
| 1986-1992 | Studies of Human Medicine, University of Munich, LMU |